Tesamorelin — GHRH Analogue for Metabolic and Neuroscience Research
Tesamorelin is a synthetic 44-amino acid peptide analogue of Growth Hormone-Releasing Hormone (GHRH). As the only FDA-approved treatment for HIV-associated lipodystrophy, Tesamorelin has been extensively characterized in clinical research for its effects on visceral adipose tissue reduction, cognitive function, and neuroprotection.
Key Specifications
- Length: 44 amino acids
- Type: GHRH analogue
- Purity: >99% (HPLC verified)
- Available Sizes: 5mg, 10mg per vial
- Storage: 2-8°C (lyophilized)
Research Applications
- Visceral adipose tissue reduction mechanisms
- Growth hormone axis pharmacology
- HIV-associated metabolic complications
- Cognitive function and neuroprotection
- Body composition and metabolic health
- Lipodystrophy pathophysiology
Frequently Asked Questions
What distinguishes Tesamorelin from other GHRH analogues?
Tesamorelin is the most clinically characterized GHRH analogue, with extensive research on visceral fat reduction. Its 44-amino acid structure provides high receptor specificity, making it an excellent tool for studying the GH/IGF-1 axis and its metabolic effects.
What research areas benefit most from Tesamorelin?
Tesamorelin is particularly valuable for studies on visceral adiposity, metabolic syndrome, cognitive aging, neuroprotection, and the intersection of endocrine function with body composition.
Does RA101 provide certificates of analysis for Tesamorelin?
Yes. Every batch of Tesamorelin comes with full independent laboratory verification. CoA documentation is available upon request.
Reviews
There are no reviews yet.